LOS ANGELES, Jan. 5, 2012 /PRNewswire-iReach/ -- Gentech Pharmaceutical, announced today it will be front and center at the Golden Globe Awards introducing new products and giving away freebies to the Hollywood elite from their display area. Gentech will include its flagship weight loss product, PhenTabz as part of the giveaways as the official weight loss supplement given to celebrities at the upcoming Golden Globe awards in the GBK Gift Lounge on January 13th and 14th in Los Angeles, California.
PhenTabz will be at the awards ceremony which will be personally run by Denise Flemming, CEO of Look LA. "Denise is one of the most well-known and respected Hollywood insiders that is constantly working with the Hollywood elite to bringing them the latest and greatest in everything from fashion to designer beverages," says Derek Vest, CEO of Gentech Pharmaceutical.
The patented ingredients in PhenTabz weight loss pills perform two essential functions. It increases the body's mobility of fat, while increasing metabolic rate. PhenTabz greatly reduces appetite to ensure patients have control and motivation. PhenTabz is not an herbal supplement, but rather a designer non-prescription pharmaceutical providing superior weight loss results without the side effects. As a result, many health care professionals have upgraded their patients to PhenTabzRX as the new Phentermine replacement.
About Gentech Pharmaceutical
Gentech Pharmaceutical applies the science of perfecting and improving current medications and OTC formulations/chemical structures to produce "designer pharmacological alternatives" without the side effects. Gentech continues to broaden its' research and development efforts, with a focus on weight loss/obesity, attention deficit disorder/mental performance, diabetes, anxiety/stress relief, and anti-aging.
Gentech's product line includes: PhenTabz, PhenTabzTeen, ADDTabz and InsulTabz.
For more information, please visit www.gentech-pharmaceutical.com or call 888.666.1714.
|SOURCE Gentech Pharmaceutical|
Copyright©2010 PR Newswire.
All rights reserved